Trials / Terminated
TerminatedNCT02315144
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TV48108 | TV48108 15, 60, 120 μg |
| DRUG | Placebo | Placebo Comparator |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2014-12-11
- Last updated
- 2021-11-09
Locations
7 sites across 3 countries: United States, Australia, New Zealand
Source: ClinicalTrials.gov record NCT02315144. Inclusion in this directory is not an endorsement.